The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
ModraDoc006 Plus Ritonavir Shows Favorable Safety, Comparable Efficacy to IV Docetaxel in mCRPC
The combination of ModraDoc006—a novel, oral tablet formulation of docetaxel—and ritonavir produced comparable response rates and radiographic progression-free survival to that achieved with intravenous docetaxel in patients with metastatic castration-resistant prostate cancer.
FOR46 Shows Early Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer
The CD46-targeted antibody-drug conjugate FOR46 demonstrated encouraging evidence of antitumor activity in patients with metastatic castration-resistant prostate cancer with a safety profile that proved to be similar to other monomethyl auristatin E–based ADCs, according to data from a phase 1a/1b trial.
FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors
The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.
Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence
The peptide cancer vaccine onilcamotide failed to show superiority over placebo in terms of preventing progression in patients with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.
Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and BeyondJune 10th 2022
B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.
PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPCJune 8th 2022
Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.
PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPCJune 6th 2022
68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPCJune 5th 2022
The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.
177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After DocetaxelJune 5th 2022
177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities
Prostate Cancer Management: Future Directions in CareMay 25th 2022
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPCMay 25th 2022
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.